Search for: "Ortho-McNeil Pharmaceuticals"
Results 181 - 200
of 270
Sorted by Relevance
|
Sort by Date
13 Sep 2012, 6:48 pm
Johnson & Johnson’s Ortho-McNeil-Janssen Pharmaceuticals, Inc. has been the defendant in numerous Levaquin injury lawsuits over has tendon ruptures and permanent tendon damage. [read post]
22 Aug 2009, 11:03 pm
MANUFACTURER: Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals, Inc. [read post]
5 Jul 2011, 4:57 am
Ortho-McNeil Pharmaceutical, Inc., 2011 U.S. [read post]
22 Mar 2011, 8:34 am
” In fact, in May 2010, Ortho-McNeil Pharmaceutical LLC pleaded guilty to illegal promotion of Topamax and was sentenced to pay a criminal fine of over $6 million. [read post]
13 Sep 2012, 6:48 pm
Johnson & Johnson’s Ortho-McNeil-Janssen Pharmaceuticals, Inc. has been the defendant in numerous Levaquin injury lawsuits over has tendon ruptures and permanent tendon damage. [read post]
10 Aug 2009, 10:06 pm
Plaintiffs for Levaquin lawsuits claim the manufacturer, Ortho-McNeil-Janssen Pharmaceuticals, failed to research its product adequately prior to bringing Levaquin to market in 1996 and failed to warn about adverse effects to the tendon. [read post]
10 Mar 2010, 5:22 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc. [read post]
13 Apr 2011, 5:13 pm
Ortho-McNeil-Janssen Pharmaceuticals, Inc., No. 2-10-cv-00836 (E.D. [read post]
10 Mar 2010, 5:22 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc. [read post]
17 Nov 2010, 1:48 am
(Patently-O) US: Amicus brief filed by Alnylam Pharmaceuticals argues that Funk Bros. is about obviousness, not patent eligibility: AMP v USPTO (Holman’s Biotech IP Blog) US: Amicus briefs in AMP v USPTO: Genetic Alliance (Patent Docs) US: Patent expirations will stabilise the pharmaceutical industry (BiotechBlog) US: Generic industry headed for a ‘180-day exclusivity cliff’ (FDA Law Blog) US: PTO clarifies PTE availability in post-PhotoCure and… [read post]
14 Feb 2012, 11:50 am
Or, if knowing the largest pharmaceutical MDL to date is something you can use as an ice breaker. [read post]
13 Nov 2013, 1:13 pm
Ortho-McNeil Pharmaceutical, Inc., 2013 U.S. [read post]
28 Jul 2010, 12:06 am
(EDTexweblog.com) (Docket Report) US: Post-Bilski: Federal Circuit to reconsider diagnostic testing and medical methods – Prometheus v Mayo, Classen v Biogen (IP Spotlight) (Patently-O) US: Federal Circuit review of patent term extensions – Ortho-McNeil v Lupin, Photocure v Kappos (Patently-O) USPTO provides clarification regarding treatment of PTA letters (Patent Docs) US: Pharmaceutical reverse payments and lower drug costs: An interesting dilemma! [read post]
5 Jul 2007, 10:37 am
App. 1976).Indiana: Ortho Pharmaceutical Corp. v. [read post]
28 Oct 2009, 5:00 am
Most recently, in December 2008, a division of Ortho-McNeil-Janssen a company under Johnson & Johnson recalled defective fentanyl transdermal patches. [read post]
23 Mar 2011, 5:02 am
(Thanks again to Bloomberg.com and these reporters for the coverage).J&J’s Risperdal Letter Violated Consumer Law, Jury Finds By Jef Feeley and Gary Henderson - Mar 22, 2011 7:23 PM ETA Johnson & Johnson (JNJ) unit violated consumer-protection laws by sending South Carolina doctors a misleading letter about the safety and effectiveness of the antipsychotic drug Risperdal, a jury concluded.Jurors in state court in Spartanburg, South Carolina, deliberated more than six hours before… [read post]
27 Oct 2011, 4:24 am
That didn’t matter much to Ortho-McNeil Pharmaceutical, a Johnson & Johnson subsidiary, which: [P]romoted the sale of Topamax for off-label psychiatric uses through a practice known as the “Doctor-for-a-Day” program. [read post]
27 May 2010, 3:20 am
(Patent Docs) Levaquin (Levofloxacin) – US: When it comes to patent term extensions, an enantiomer is a different drug from racemate: Ortho-McNeil Pharma v. [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
